Brainstorm Cell Therapeutics (NASDAQ:BCLI) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a report issued on Monday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, Maxim Group raised Brainstorm Cell Therapeutics from a hold rating to a buy rating and set a $2.00 target price on the stock in a research report on Thursday, July 11th.

Brainstorm Cell Therapeutics Trading Up 4.3 %

Shares of Brainstorm Cell Therapeutics stock opened at $0.25 on Monday. Brainstorm Cell Therapeutics has a 1 year low of $0.13 and a 1 year high of $0.79. The company’s fifty day simple moving average is $0.30 and its 200-day simple moving average is $0.41. The company has a market cap of $17.84 million, a price-to-earnings ratio of -0.80 and a beta of 0.35.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.04) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.04). During the same quarter in the prior year, the company earned ($0.27) earnings per share. As a group, research analysts forecast that Brainstorm Cell Therapeutics will post -0.19 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Armistice Capital LLC purchased a new position in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned 11.30% of Brainstorm Cell Therapeutics as of its most recent SEC filing. 14.33% of the stock is currently owned by institutional investors.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.